TSPO PET for glioma imaging using the novel ligand 18F-GE-180: first results in patients with glioblastoma

被引:87
作者
Albert, Nathalie L. [1 ,2 ,3 ,4 ]
Unterrainer, M. [1 ]
Fleischmann, D. F. [2 ,3 ,5 ]
Lindner, S. [1 ]
Vettermann, F. [1 ]
Brunegraf, A. [1 ]
Vomacka, L. [1 ]
Brendel, M. [1 ]
Wenter, V. [1 ]
Wetzel, C. [6 ]
Rupprecht, R. [6 ]
Tonn, J. -C. [2 ,3 ,7 ]
Belka, C. [2 ,3 ,5 ]
Bartenstein, P. [1 ,2 ,3 ,4 ]
Niyazi, M. [2 ,3 ,5 ]
机构
[1] Ludwig Maximilians Univ Munchen, Dept Nucl Med, Marchioninistr 15, D-81377 Munich, Germany
[2] German Canc Consortium DKTK, Partner Site Munich, Heidelberg, Germany
[3] German Canc Res Ctr, Heidelberg, Germany
[4] Bunich Cluster Syst Neurol SyNergy, Munich, Germany
[5] Ludwig Maximilians Univ Munchen, Dept Radiat Oncol, Munich, Germany
[6] Univ Regensburg, Dept Psychiat & Psychotherapy, Regensburg, Germany
[7] Ludwig Maximilians Univ Munchen, Dept Neurosurg, Munich, Germany
关键词
Glioma; F-18-GE-180; TSPOPET; Radiotherapy planning; POSITRON-EMISSION-TOMOGRAPHY; BENZODIAZEPINE-BINDING-SITES; TRANSLOCATOR PROTEIN; F-18-FET PET; MICROGLIAL ACTIVATION; EXPRESSION; BRAIN; DIAGNOSIS; TRACER; GRADE;
D O I
10.1007/s00259-017-3799-9
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Objective The 18-kDa mitochondrial translocator protein (TSPO) was reported to be upregulated in gliomas. F-18-GE-180 is a novel 3rd generation TSPO receptor ligand with improved target-to-background contrast compared to previous tracers. In this pilot study, we compared PET imaging with F-18-GE-180 and MRI of patients with untreated and recurrent pretreated glioblastoma. Methods Eleven patients with histologically confirmed IDH wildtype gliomas (10 glioblastomas, 1 anaplastic astrocytoma) underwent F-18-GE-180 PET at initial diagnosis or recurrence. The PET parameters mean background uptake (SUVBG), maximal tumour-to-background ratio (TBRmax) and PET volume using different thresholds (SUVBG x 1.6, 1.8 and 2.0) were evaluated in the 60-80 min p.i. summation images. The different PET volumes were compared to the contrast-enhancing tumour volume on MRI. Results All gliomas were positive on F-18-GE-180 PET and were depicted with extraordinarily high tumour-to-background contrast (median SUVBG 0.47 (0.37-0.93), TBRmax 6.61 (3.88-9.07)). F-18-GE-180 uptake could be found even in areas without contrast enhancement on MRI, leading to significantly larger PET volumes than MRI-based volumes (median 90.5, 74.5, and 63.8 mL vs. 31.0 mL; p = 0.003, 0.004, 0.013). In percentage difference, the PET volumes were on average 179%, 135%, and 90% larger than the respective MRI volumes. The median spatial volumetric correlation (Sorensen-Dice coefficient) of PET volumes and MRI volumes prior to radiotherapy was 0.48, 0.54, and 0.58. Conclusion F-18-GE-180 PET provides a remarkably high tumour-to-background contrast in untreated and pretreated glioblastoma and shows tracer uptake even beyond contrast enhancement on MRI. To what extent F-18-GE-180 uptake reflects the tumour extent of human gliomas and inflammatory cells remains to be evaluated in future prospective studies with guided stereotactic biopsies and correlation of histopathological results.
引用
收藏
页码:2230 / 2238
页数:9
相关论文
共 47 条
[41]   Quantitative Preclinical Imaging of TSPO Expression in Glioma Using N,N-Diethyl-2-(2(4-(2-18F-Fluoroethoxy)Phenyl)-5,7-Dimethylpyrazolo[1,5-a]Pyrimidin-3-yl)Acetamide [J].
Tang, Dewei ;
Hight, Matthew R. ;
McKinley, Eliot T. ;
Fu, Allie ;
Buck, Jason R. ;
Smith, R. Adam ;
Tantawy, Mohammed Noor ;
Peterson, Todd E. ;
Colvin, Daniel C. ;
Ansari, M. Sib ;
Nickels, Michael ;
Manning, H. Charles .
JOURNAL OF NUCLEAR MEDICINE, 2012, 53 (02) :287-294
[42]   Utilization of PET imaging in differential diagnostics between a tumefactive multiple sclerosis lesion and low-grade glioma [J].
Tarkkonen, Aleksi ;
Rissanen, Eero ;
Tuokkola, Terhi ;
Airas, Laura .
MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2016, 9 :147-149
[43]   Immunohistochemical expression of peripheral benzodiazepine receptors in human astrocytomas and its correlation with grade of malignancy, proliferation, apoptosis and survival [J].
Vlodavsky, Eugene ;
Soustiel, Jean F. .
JOURNAL OF NEURO-ONCOLOGY, 2007, 81 (01) :1-7
[44]  
Vomacka L, 2017, J NUCL MED, V58
[45]   [18F]GE-180: A novel fluorine-18 labelled PET tracer for imaging Translocator protein 18 kDa (TSPO) [J].
Wadsworth, Harry ;
Jones, Paul A. ;
Chau, Wai-Fung ;
Durrant, Clare ;
Fouladi, Naghmeh ;
Passmore, Joanna ;
O'Shea, Dennis ;
Wynn, Duncan ;
Morisson-Iveson, Veronique ;
Ewan, Amanda ;
Thaning, Mikkel ;
Mantzilas, Dimitrios ;
Gausemel, Ingvil ;
Khan, Imtiaz ;
Black, Andrew ;
Avory, Michelle ;
Trigg, William .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2012, 22 (03) :1308-1313
[46]   EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma [J].
Weller, Michael ;
van den Bent, Martin ;
Hopkins, Kirsten ;
Tonn, Joerg C. ;
Stupp, Roger ;
Falini, Andrea ;
Cohen-Jonathan-Moyal, Elizabeth ;
Frappaz, Didier ;
Henriksson, Roger ;
Balana, Carmen ;
Chinot, Olivier ;
Ram, Zvi ;
Reifenberger, Guido ;
Soffietti, Riccardo ;
Wick, Wolfgang .
LANCET ONCOLOGY, 2014, 15 (09) :E395-E403
[47]   The translocator protein ligand [18F]DPA-714 images glioma and activated microglia in vivo [J].
Winkeler, Alexandra ;
Boisgard, Raphael ;
Awde, Ali R. ;
Dubois, Albertine ;
Theze, Benoit ;
Zheng, Jinzi ;
Ciobanu, Luisa ;
Dolle, Frederic ;
Viel, Thomas ;
Jacobs, Andreas H. ;
Tavitian, Bertrand .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2012, 39 (05) :811-823